Production method of thiazole derivative
Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A 2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, analgesic resistance to opioid, migraine, movement disorder, depression, anxiety disorder and the like. Also provided is a production method of a compound represented by the formula (C), which contains (i) a step of reacting a compound represented by the formula (A) and a compound represented by the formula (B), and the like: (wherein R 1 represents furyl, R 4 , R 5 and R 6 are the same or different and each represents lower alkyl or aryl, R 2 represents pyridyl or tetrahydropyranyl, and X 1 represents halogen).
1. An anhydrous crystal of a compound represented by formula (IA)
said anhydrous crystal having at least one peak at 8.3°, 20.8°, 21.2° or 22.4° for the angles of diffraction (2θ±0.2°) as determined by powder X-ray diffraction.
2. The crystal according to claim 1 , which has peaks at 8.3° and 19.1° for the angles of diffraction (2θ±0.2°) as determined by powder X-ray diffraction.
3. The crystal according to claim 1 , which has peaks at 21.2°, 23.8° and 27.0° for the angles of diffraction (20±0.2°) as determined by powder X-ray diffraction.
4. A production method of the crystal described in claim 1 , comprising a step of crystallizing a compound represented by the formula (IA) from isobutyl alcohol.
5. The crystal according to claim 2 , which has peaks at 21.2°, 23.8° and 27.0° for the angles of diffraction (20±0.2°) as determined by powder X-ray diffraction.
6. A production method of the crystal described in claim 2 , comprising a step of crystallizing a compound represented by the formula (IA) from isobutyl alcohol.
7. A production method of the crystal described in claim 3 , comprising a step of crystallizing a compound represented by the formula (IA) from isobutyl alcohol.
8. A production method of the crystal described in claim 5 , comprising a step of crystallizing a compound represented by the formula (IA) from isobutyl alcohol.